Arch Therapeutics Inc (OTCBB:ARTH)’s Pump Revived

“It’s alive!”, said Dr. Frankenstein when his creature began to move in the famous horror film. What did the pumpers say when they watched Arch Therapeutics Inc (OTCBB:ARTH)’s performance during yesterday’s session? Pretty much the same thing: “It’s alive… again!”. But have they created a monster?

Well, if it’s true that a picture says a thousand words, then the chart on the right should speak volumes. It all started at the beginning of July, not more than a month after ARTH had turned into a life science company, when a landing page was set up. The ticker had already gathered plenty of attention, but when the website went online, trading absolutely exploded. Just two sessions were enough for the price to smash through the $1 per share barrier and to register a 52-week high of $1.36. Unfortunately, these heights proved to be too much for the newly born company.

The following days ended with some minor losses, but at one point, on July 15, ARTH went completely out of control. After a few heavy blows, it was standing at $0.45 and despite the continuous efforts from the pumpers, the hard mailers disclosing a $2.9 million budget and the optimistic press releases coming out of the company HQ, the price was never going to get back the the hype-induced heights.

On August 22, the alerts through the emails stopped and most people thought that this will be the end of it. On Sunday, however, the pumpers showed that this is definitely not the case.

A total of ten emails flooded investors’ inboxes before the start of yesterday’s session and the result of the renewed effort is… a 3% loss. More than 1.2 million shares changed hands pushing the dollar volume to around $466 thousand which suggests that people are still losing money, but we should point out that a further fifteen alerts have been received (with more coming in as we speak) which will probably bring another exciting day of trading. Some of the pumpers claim that ARTH hides great long-term potential, while other say that the monumental performance from the upcoming few days “is in the cards”. Will this push the ticker in the right direction, though?

When it comes to volatile penny stocks, it’s really hard to predict with any sort of certainty what exactly is going to happen next, but the fact remains that there aren’t many things to support the promoters’ claims. The latest announcements to come out of ARTH‘s HQ concern their participation in some medical symposiums and while this gives the ticker a bit more exposure, it’s hardly informative of what’s happening to the flagship product, the revolutionary AC5 hemostasis gel.

The peculiar thing is, right now, with the ongoing promotion, the developments around the product are not really all that important. Quite a lot of cash was shed on the pump and we’re pretty sure that, since there are still emails flying around, some people have yet to get their investments back. As you probably know, this will, most likely, depress the price and if you get caught off-guard, the losses could be hard to swallow.

How hard? Well, you can ask the people who got surprised by Nutranomics, Inc. f/k/a Buka Ventures, Inc. (OTCBB:NNRX)’s and Alkaline Water Company Inc (OTCBB:WTER)’s horrific crashes from yesterday. Of course, you can also have a quick peek at the charts on the right and see for yourself.